Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.40 |
| ▸ | CCNC | P24863 | 5/20 | 0.40 |
| ▸ | CDK8 | P49336 | 5/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.39 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14730723 | 0.78 | KDR (0.43) | TLR8TLR7TLR9 | |
| SCHEMBL14730803 | 0.77 | KDM5A (0.38) | KDM5ATLR8TLR7TLR9 | |
| SCHEMBL14730773 | 0.76 | TLR9 (0.38) | KDM5ATLR8TLR7TLR9 | |
| SCHEMBL14730801 | 0.76 | KDM5A (0.48) | KDM5ATLR8TLR7TLR9 | |
| SCHEMBL14730716 | 0.76 | ALK (0.46) | TLR8TLR7TLR9 | |
| SCHEMBL14730713 | 0.75 | KDM5A (0.39) | KDM5ATLR8TLR7TLR9 | |
| SCHEMBL16248388 | 0.74 | TLR9 (0.43) | KDM5ATLR8TLR7TLR9 | |
| SCHEMBL14730802 | 0.74 | TLR9 (0.41) | TLR8TLR7TLR9 | |
| SCHEMBL14730721 | 0.74 | USP30 (0.49) | USP30 | |
| SCHEMBL14730726 | 0.73 | RAB9A (0.45) | TLR8TLR7TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-9340539-B2 | Hepatitis C inhibitor compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| WO-2013026163-A1 | HEPATITIS C INHIBITOR COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343077-A1 | HEPATITIS C INHIBITOR COMPOUNDS | HCCS, C1R, HAVCR2 | KDM5A 4381/4885USP30 1713/4885CCNC 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.